Insider · CIK 0001662392
Colin John Meyer
Files at RETA (REATA PHARMACEUTICALS INC). First filing Mar 6, 2023, latest Mar 8, 2023.
In brief
Colin John Meyer files SEC Form 4 as officer at RETA (REATA PHARMACEUTICALS INC). Since Mar 6, 2023, Colin John Meyer has reported 0 open-market buys worth $0 and 2 open-market sells worth $8.2M, the latest filed on Mar 8, 2023.
A track record needs three past buys with six months of prices behind them; Colin John Meyer has 0, so none is measured yet.
The newest scored trade: sold $53k of RETA on Mar 7, 2023, filed Mar 8, 2023, scored 37 (weak).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | REATA PHARMACEUTICALS INC | $53k 621 shares | -1% | - | |
| 60Notable | REATA PHARMACEUTICALS INC | $8.1M 93,922 shares | -52% | - |
Transactions
Every row this insider has filed, 15 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 7, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -621 | $84.57 | $53k | 84,606 | Mar 8, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | CConversion Class A common stock | +88,636 | - | - | 179,149 | Mar 6, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -22,752 | $85.23 | $1.9M | 156,397 | Mar 6, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -34,794 | $86.49 | $3.0M | 121,603 | Mar 6, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -19,099 | $87.55 | $1.7M | 102,504 | Mar 6, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -11,181 | $88.50 | $990k | 91,323 | Mar 6, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -810 | $90.58 | $73k | 90,513 | Mar 6, 2023 |
| Mar 3, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -5,286 | $87.35 | $462k | 85,227 | Mar 6, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | MOption exercise Employee Stock Option (right to buy)derivative | -88,636 | $0.00 | $0 | 0 | Mar 6, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | MOption exercise Class B common stockderivative | +88,636 | $11.00 | $975k | 162,940 | Mar 6, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | CConversion Class B common stockderivative | -88,636 | - | - | 74,304 | Mar 6, 2023 |
| Feb 28, 2023 | RETA REATA PHARMACEUTICALS INC | AGrant or award Class A common stock | +15,000 | $0.00 | $0 | 90,513 | Mar 1, 2023 |
| Feb 28, 2023 | RETA REATA PHARMACEUTICALS INC | AGrant or award Employee Stock Option (right-to-buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Mar 1, 2023 |
| Jan 3, 2023 | RETA REATA PHARMACEUTICALS INC | AGrant or award Class A common stock | +23,513 | $0.00 | $0 | 75,513 | Jan 4, 2023 |
| Jan 3, 2023 | RETA REATA PHARMACEUTICALS INC | AGrant or award Employee Stock Option (right-to-buy)derivative | +95,475 | $0.00 | $0 | 95,475 | Jan 4, 2023 |
Questions about Colin John Meyer
Answered from the filings on this page, as of the latest one.
Is Colin John Meyer buying or selling?
Not in the last 12 months. Colin John Meyer's latest open-market trade on SEC Form 4 was sold $53k of RETA on Mar 7, 2023.
How did Colin John Meyer's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Colin John Meyer has 0.
Where does Colin John Meyer file Form 4?
Colin John Meyer has filed Form 4 at RETA (REATA PHARMACEUTICALS INC) as Chief Innovation Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.